Does the media favor APGE or BIIB?

In the previous week, Biogen had 3 more articles in the media than Apogee Therapeutics. MarketBeat recorded 15 mentions for Biogen and 12 mentions for Apogee Therapeutics. Biogen's average media sentiment score of 0.94 beat Apogee Therapeutics' score of 0.68 indicating that Biogen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Apogee Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Biogen 7 Very Positive mention(s) 4 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ALNY or APGE?

In the previous week, Alnylam Pharmaceuticals had 16 more articles in the media than Apogee Therapeutics. MarketBeat recorded 28 mentions for Alnylam Pharmaceuticals and 12 mentions for Apogee Therapeutics. Apogee Therapeutics' average media sentiment score of 0.68 beat Alnylam Pharmaceuticals' score of 0.04 indicating that Apogee Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alnylam Pharmaceuticals 6 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 5 Negative mention(s) 0 Very Negative mention(s) Neutral Apogee Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ROIV or APGE?

In the previous week, Roivant Sciences had 5 more articles in the media than Apogee Therapeutics. MarketBeat recorded 17 mentions for Roivant Sciences and 12 mentions for Apogee Therapeutics. Roivant Sciences' average media sentiment score of 0.97 beat Apogee Therapeutics' score of 0.68 indicating that Roivant Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Roivant Sciences 8 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Apogee Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor INCY or APGE?

In the previous week, Apogee Therapeutics had 2 more articles in the media than Incyte. MarketBeat recorded 12 mentions for Apogee Therapeutics and 10 mentions for Incyte. Incyte's average media sentiment score of 0.94 beat Apogee Therapeutics' score of 0.68 indicating that Incyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Incyte 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Apogee Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor APGE or BNTX?

In the previous week, BioNTech had 12 more articles in the media than Apogee Therapeutics. MarketBeat recorded 24 mentions for BioNTech and 12 mentions for Apogee Therapeutics. Apogee Therapeutics' average media sentiment score of 0.68 beat BioNTech's score of -0.11 indicating that Apogee Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Apogee Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioNTech 4 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 8 Negative mention(s) 0 Very Negative mention(s) Neutral

Apogee Therapeutics (APGE) Competitors

$134.63 -0.21 (-0.15%)

As of 12:03 PM Eastern

Compare

APGE vs. BIIB, ALNY, ROIV, INCY, and BNTX

Should you buy Apogee Therapeutics stock or one of its competitors? MarketBeat compares Apogee Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Apogee Therapeutics include Biogen (BIIB), Alnylam Pharmaceuticals (ALNY), Roivant Sciences (ROIV), Incyte (INCY), and BioNTech (BNTX). These companies are all part of the "biotechnology" industry.

How does Apogee Therapeutics compare to Biogen?

Apogee Therapeutics (NASDAQ:APGE) and Biogen (NASDAQ:BIIB) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, analyst recommendations, valuation, profitability, dividends and risk.

Apogee Therapeutics has a beta of 0.35, suggesting that its share price is 65% less volatile than the broader market. Comparatively, Biogen has a beta of 0.17, suggesting that its share price is 83% less volatile than the broader market.

Apogee Therapeutics currently has a consensus target price of $121.25, indicating a potential downside of 9.97%. Biogen has a consensus target price of $224.61, indicating a potential upside of 8.33%. Given Biogen's stronger consensus rating and higher probable upside, analysts plainly believe Biogen is more favorable than Apogee Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apogee Therapeutics	1 Sell rating(s)	15 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.24
Biogen	1 Sell rating(s)	13 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.56

Biogen has higher revenue and earnings than Apogee Therapeutics. Apogee Therapeutics is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apogee Therapeutics	N/A	N/A	-$255.84M	-$4.33	N/A
Biogen	$9.89B	3.10	$1.29B	$5.65	36.70

79.0% of Apogee Therapeutics shares are held by institutional investors. Comparatively, 87.9% of Biogen shares are held by institutional investors. 24.3% of Apogee Therapeutics shares are held by company insiders. Comparatively, 0.3% of Biogen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Biogen had 3 more articles in the media than Apogee Therapeutics. MarketBeat recorded 15 mentions for Biogen and 12 mentions for Apogee Therapeutics. Biogen's average media sentiment score of 0.94 beat Apogee Therapeutics' score of 0.68 indicating that Biogen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Apogee Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Biogen	7 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Biogen has a net margin of 8.32% compared to Apogee Therapeutics' net margin of 0.00%. Biogen's return on equity of 11.18% beat Apogee Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apogee Therapeutics	N/A	-32.64%	-31.25%
Biogen	8.32%	11.18%	6.88%

Summary

Biogen beats Apogee Therapeutics on 13 of the 15 factors compared between the two stocks.

How does Apogee Therapeutics compare to Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals (NASDAQ:ALNY) and Apogee Therapeutics (NASDAQ:APGE) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, analyst recommendations, institutional ownership, dividends, profitability, earnings and risk.

93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. Comparatively, 79.0% of Apogee Therapeutics shares are held by institutional investors. 0.9% of Alnylam Pharmaceuticals shares are held by company insiders. Comparatively, 24.3% of Apogee Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Alnylam Pharmaceuticals had 16 more articles in the media than Apogee Therapeutics. MarketBeat recorded 28 mentions for Alnylam Pharmaceuticals and 12 mentions for Apogee Therapeutics. Apogee Therapeutics' average media sentiment score of 0.68 beat Alnylam Pharmaceuticals' score of 0.04 indicating that Apogee Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alnylam Pharmaceuticals	6 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	5 Negative mention(s)	0 Very Negative mention(s)	Neutral
Apogee Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Alnylam Pharmaceuticals presently has a consensus target price of $396.72, indicating a potential upside of 81.31%. Apogee Therapeutics has a consensus target price of $121.25, indicating a potential downside of 9.97%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts clearly believe Alnylam Pharmaceuticals is more favorable than Apogee Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alnylam Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	16 Buy rating(s)	3 Strong Buy rating(s)	2.92
Apogee Therapeutics	1 Sell rating(s)	15 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.24

Alnylam Pharmaceuticals has a net margin of 15.26% compared to Apogee Therapeutics' net margin of 0.00%. Alnylam Pharmaceuticals' return on equity of 84.93% beat Apogee Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alnylam Pharmaceuticals	15.26%	84.93%	14.30%
Apogee Therapeutics	N/A	-32.64%	-31.25%

Alnylam Pharmaceuticals has a beta of 0.3, suggesting that its stock price is 70% less volatile than the broader market. Comparatively, Apogee Therapeutics has a beta of 0.35, suggesting that its stock price is 65% less volatile than the broader market.

Alnylam Pharmaceuticals has higher revenue and earnings than Apogee Therapeutics. Apogee Therapeutics is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alnylam Pharmaceuticals	$3.71B	7.88	$313.75M	$5.38	40.67
Apogee Therapeutics	N/A	N/A	-$255.84M	-$4.33	N/A

Summary

Alnylam Pharmaceuticals beats Apogee Therapeutics on 13 of the 16 factors compared between the two stocks.

How does Apogee Therapeutics compare to Roivant Sciences?

Roivant Sciences (NASDAQ:ROIV) and Apogee Therapeutics (NASDAQ:APGE) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, valuation, profitability, earnings, institutional ownership and media sentiment.

64.8% of Roivant Sciences shares are owned by institutional investors. Comparatively, 79.0% of Apogee Therapeutics shares are owned by institutional investors. 8.8% of Roivant Sciences shares are owned by insiders. Comparatively, 24.3% of Apogee Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Roivant Sciences currently has a consensus price target of $34.77, indicating a potential downside of 4.64%. Apogee Therapeutics has a consensus price target of $121.25, indicating a potential downside of 9.97%. Given Roivant Sciences' stronger consensus rating and higher probable upside, analysts clearly believe Roivant Sciences is more favorable than Apogee Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83
Apogee Therapeutics	1 Sell rating(s)	15 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.24

Apogee Therapeutics has a net margin of 0.00% compared to Roivant Sciences' net margin of -3,534.96%. Roivant Sciences' return on equity of -22.94% beat Apogee Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-3,534.96%	-22.94%	-21.53%
Apogee Therapeutics	N/A	-32.64%	-31.25%

Apogee Therapeutics has lower revenue, but higher earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Apogee Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$7.53M	3,482.33	-$299.77M	-$0.53	N/A
Apogee Therapeutics	N/A	N/A	-$255.84M	-$4.33	N/A

Roivant Sciences has a beta of 1.12, suggesting that its stock price is 12% more volatile than the broader market. Comparatively, Apogee Therapeutics has a beta of 0.35, suggesting that its stock price is 65% less volatile than the broader market.

In the previous week, Roivant Sciences had 5 more articles in the media than Apogee Therapeutics. MarketBeat recorded 17 mentions for Roivant Sciences and 12 mentions for Apogee Therapeutics. Roivant Sciences' average media sentiment score of 0.97 beat Apogee Therapeutics' score of 0.68 indicating that Roivant Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Roivant Sciences	8 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Apogee Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Roivant Sciences beats Apogee Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Apogee Therapeutics compare to Incyte?

Incyte (NASDAQ:INCY) and Apogee Therapeutics (NASDAQ:APGE) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, valuation, risk, earnings, profitability, institutional ownership and analyst recommendations.

Incyte has higher revenue and earnings than Apogee Therapeutics. Apogee Therapeutics is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Incyte	$5.14B	4.82	$1.29B	$7.85	15.57
Apogee Therapeutics	N/A	N/A	-$255.84M	-$4.33	N/A

Incyte has a beta of 0.76, suggesting that its stock price is 24% less volatile than the broader market. Comparatively, Apogee Therapeutics has a beta of 0.35, suggesting that its stock price is 65% less volatile than the broader market.

In the previous week, Apogee Therapeutics had 2 more articles in the media than Incyte. MarketBeat recorded 12 mentions for Apogee Therapeutics and 10 mentions for Incyte. Incyte's average media sentiment score of 0.94 beat Apogee Therapeutics' score of 0.68 indicating that Incyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Incyte	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Apogee Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

97.0% of Incyte shares are owned by institutional investors. Comparatively, 79.0% of Apogee Therapeutics shares are owned by institutional investors. 16.2% of Incyte shares are owned by company insiders. Comparatively, 24.3% of Apogee Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Incyte has a net margin of 27.71% compared to Apogee Therapeutics' net margin of 0.00%. Incyte's return on equity of 29.93% beat Apogee Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Incyte	27.71%	29.93%	22.88%
Apogee Therapeutics	N/A	-32.64%	-31.25%

Incyte presently has a consensus target price of $120.40, indicating a potential downside of 1.51%. Apogee Therapeutics has a consensus target price of $121.25, indicating a potential downside of 9.97%. Given Incyte's stronger consensus rating and higher probable upside, equities research analysts plainly believe Incyte is more favorable than Apogee Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Incyte	0 Sell rating(s)	13 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.43
Apogee Therapeutics	1 Sell rating(s)	15 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.24

Summary

Incyte beats Apogee Therapeutics on 13 of the 16 factors compared between the two stocks.

How does Apogee Therapeutics compare to BioNTech?

Apogee Therapeutics (NASDAQ:APGE) and BioNTech (NASDAQ:BNTX) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, media sentiment, dividends, profitability, valuation and earnings.

In the previous week, BioNTech had 12 more articles in the media than Apogee Therapeutics. MarketBeat recorded 24 mentions for BioNTech and 12 mentions for Apogee Therapeutics. Apogee Therapeutics' average media sentiment score of 0.68 beat BioNTech's score of -0.11 indicating that Apogee Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Apogee Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioNTech	4 Very Positive mention(s)	1 Positive mention(s)	8 Neutral mention(s)	8 Negative mention(s)	0 Very Negative mention(s)	Neutral

79.0% of Apogee Therapeutics shares are owned by institutional investors. Comparatively, 15.5% of BioNTech shares are owned by institutional investors. 24.3% of Apogee Therapeutics shares are owned by insiders. Comparatively, 19.2% of BioNTech shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Apogee Therapeutics has higher earnings, but lower revenue than BioNTech. Apogee Therapeutics is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apogee Therapeutics	N/A	N/A	-$255.84M	-$4.33	N/A
BioNTech	$3.25B	7.31	-$1.29B	-$7.83	N/A

Apogee Therapeutics has a net margin of 0.00% compared to BioNTech's net margin of -63.54%. BioNTech's return on equity of -6.86% beat Apogee Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apogee Therapeutics	N/A	-32.64%	-31.25%
BioNTech	-63.54%	-6.86%	-6.00%

Apogee Therapeutics has a beta of 0.35, indicating that its stock price is 65% less volatile than the broader market. Comparatively, BioNTech has a beta of 1.27, indicating that its stock price is 27% more volatile than the broader market.

Apogee Therapeutics presently has a consensus target price of $121.25, suggesting a potential downside of 9.97%. BioNTech has a consensus target price of $127.81, suggesting a potential upside of 36.21%. Given BioNTech's stronger consensus rating and higher probable upside, analysts plainly believe BioNTech is more favorable than Apogee Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apogee Therapeutics	1 Sell rating(s)	15 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.24
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74

Summary

BioNTech beats Apogee Therapeutics on 9 of the 15 factors compared between the two stocks.

Get Apogee Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding APGE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

APGE vs. The Competition

Export

Metric	Apogee Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$8.33B	$3.71B	$7.03B	$12.96B
Dividend Yield	N/A	3.76%	2.58%	10.20%
P/E Ratio	-31.10	9.06	269.91	24.87
Price / Sales	N/A	1,278.42	654.69	108.21
Price / Cash	N/A	44.95	28.89	37.44
Price / Book	10.18	17.97	11.40	6.45
Net Income	-$255.84M	-$13.25M	$3.45B	$347.50M
7 Day Performance	0.42%	5.58%	3.66%	3.77%
1 Month Performance	0.77%	-1.60%	-0.49%	-0.40%
1 Year Performance	280.55%	61.32%	77.51%	23.55%

Apogee Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
APGE Apogee Therapeutics	1.8483 of 5 stars	$134.63 -0.2%	$121.25 -9.9%	+281.0%	$8.33B	N/A	N/A	91	Earnings Report Insider Trade
BIIB Biogen	3.926 of 5 stars	$204.31 +1.2%	$223.89 +9.6%	+59.1%	$30.19B	$9.89B	36.16	7,500
ALNY Alnylam Pharmaceuticals	4.7282 of 5 stars	$216.14 -1.9%	$401.24 +85.6%	-50.1%	$28.94B	$3.71B	40.20	2,770	Analyst Revision
ROIV Roivant Sciences	1.5127 of 5 stars	$34.06 +2.2%	$33.59 -1.4%	+216.3%	$24.57B	$8.26M	N/A	860	Analyst Forecast
INCY Incyte	3.3926 of 5 stars	$118.83 +0.3%	$119.60 +0.7%	+53.8%	$24.09B	$5.14B	15.14	2,844

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:APGE) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Apogee Therapeutics (APGE) Competitors

APGE vs. BIIB, ALNY, ROIV, INCY, and BNTX

How does Apogee Therapeutics compare to Biogen?

Summary

How does Apogee Therapeutics compare to Alnylam Pharmaceuticals?

Summary

How does Apogee Therapeutics compare to Roivant Sciences?

Summary

How does Apogee Therapeutics compare to Incyte?

Summary

How does Apogee Therapeutics compare to BioNTech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

APGE vs. The Competition

Apogee Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Apogee Therapeutics (APGE) Competitors

APGE vs. BIIB, ALNY, ROIV, INCY, and BNTX

How does Apogee Therapeutics compare to Biogen?

Which has more risk and volatility, APGE or BIIB?

Do analysts rate APGE or BIIB?

Which has higher valuation & earnings, APGE or BIIB?

Do insiders and institutionals have more ownership in APGE or BIIB?

Does the media favor APGE or BIIB?

Is APGE or BIIB more profitable?

Summary

How does Apogee Therapeutics compare to Alnylam Pharmaceuticals?

Do institutionals & insiders believe in ALNY or APGE?

Does the media favor ALNY or APGE?

Do analysts recommend ALNY or APGE?

Is ALNY or APGE more profitable?

Which has more risk and volatility, ALNY or APGE?

Which has preferable earnings and valuation, ALNY or APGE?

Summary

How does Apogee Therapeutics compare to Roivant Sciences?

Do institutionals and insiders believe in ROIV or APGE?

Do analysts prefer ROIV or APGE?

Is ROIV or APGE more profitable?

Which has better earnings & valuation, ROIV or APGE?

Which has more volatility and risk, ROIV or APGE?

Does the media prefer ROIV or APGE?

Summary

How does Apogee Therapeutics compare to Incyte?

Which has preferable valuation and earnings, INCY or APGE?

Which has more volatility & risk, INCY or APGE?

Does the media favor INCY or APGE?

Do institutionals and insiders believe in INCY or APGE?

Is INCY or APGE more profitable?

Do analysts rate INCY or APGE?

Summary

How does Apogee Therapeutics compare to BioNTech?

Does the media favor APGE or BNTX?

Do insiders and institutionals hold more shares of APGE or BNTX?

Which has higher earnings & valuation, APGE or BNTX?

Is APGE or BNTX more profitable?

Which has more risk & volatility, APGE or BNTX?

Do analysts rate APGE or BNTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

APGE vs. The Competition

Apogee Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools